Yes. 5-Amino-1MQ is a compounded prescription medication. A telehealth consultation and medical intake are required before dispensing to ensure this formulation is appropriate for your health history, goals, and current medications.

At therapeutic doses (50mg daily), 5-Amino-1MQ is generally well-tolerated. Reported and plausible side effects include mild gastrointestinal symptoms (nausea, loose stools) during initiation, appetite suppression that may become marked in some patients, and transient fatigue during the initial metabolic adaptation phase as fat oxidation increases. Because NNMT inhibition shifts one-carbon metabolism, theoretical effects on methylation balance exist at higher doses — including mild headache or mood changes if nicotinamide substrate is insufficient. No cardiovascular, hepatotoxic, or hormonal side effects have been identified in current literature, though long-term human safety data remain limited. Patients should maintain adequate dietary protein and consider co-administration of NMN or NR to ensure substrate availability for the redirected NAD+ salvage pathway.

5-Amino-1MQ is not appropriate for everyone. It should be avoided during pregnancy or breastfeeding, as NNMT plays a role in placental metabolism and no safety data exists in these populations. Patients with a personal or family history of cancer should use caution, as NNMT inhibition alters methylation and one-carbon metabolism in ways that are not fully characterized oncologically. Those with severe liver or kidney disease, active eating disorders, or uncontrolled thyroid dysfunction should not use this compound. It is not studied in children or adolescents and is not indicated for these age groups. Patients taking MAO inhibitors or other agents that significantly alter nicotinamide metabolism should avoid concurrent use until formally studied. For best results, patients should maintain adequate protein and NAD+ precursor intake (e.g., NMN or NR), as NNMT inhibition works by redirecting nicotinamide toward NAD+ synthesis — a process that requires sufficient substrate to be effective.

Formal drug interaction studies for 5-Amino-1MQ have not been conducted. Patients on NAD+ precursors (NMN, NR, nicotinamide) may experience additive metabolic benefits — this combination is generally favorable under provider supervision. Patients on metformin or other insulin-sensitizing agents should disclose concurrent use, as additive effects on glucose metabolism are possible. Patients on PARP inhibitors should disclose, as PARP enzymes consume NAD+ and alterations in NAD+ availability may affect their activity. Patients with a history of malignancy should inform their provider, as NNMT inhibition affects cellular metabolism broadly and some cancer cells overexpress NNMT. Always provide a complete medication and supplement list before beginning treatment.

Patients with insulin resistance, metabolic syndrome, obesity, or NAFLD are among the strongest candidates for this formulation and may benefit significantly under provider supervision. Patients with significant hepatic impairment require individualized dosing review, as hepatic metabolism may be altered. Patients with a history of malignancy should disclose this before starting treatment, which will be determined at the provider's discretion based on oncological history. 5-Amino-1MQ is not indicated for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. This formulation is not indicated for patients under 18. Your provider requires a complete medical history before prescribing.